InnoSIGN welcomes Mark Oldroyd as Board Member
NewsInnoSIGN welcomes Mark Oldroyd as an Independent Board Member to the Board of Directors.
Mr. Oldroyd brings nearly 30 years of healthcare industry experience to the board at InnoSIGN. His career has focused on commercialization in startup organizations with assets in therapeutics, diagnostics, equipment, and devices. Most recently he served as Chief Business Officer at C2i Genomics and is now Chief Commercial Officer at Culmination Bio.
Mr. Oldroyd has provided advisory services to many small companies and still coaches stealth stage startups at Lionbird, a venture fund in Israel. He is formally trained in law with a specialty in health policy.
Mr. Oldroyd enjoys his down time exploring remote areas of the western US as a private pilot, or on an adventure motorcycle. He has five adult children and two grandsons.